Literature DB >> 7472417

Cannabinoids activate an inwardly rectifying potassium conductance and inhibit Q-type calcium currents in AtT20 cells transfected with rat brain cannabinoid receptor.

K Mackie1, Y Lai, R Westenbroek, R Mitchell.   

Abstract

Rat brain cannabinoid receptor (CB-1) was stably transfected into the murine tumor line AtT-20 to study its coupling to inwardly rectifying potassium currents (Kir) and high voltage-activated calcium currents (ICa). In cells expressing CB-1 ("A-2" cells), cannabinoid agonist potently and stereospecifically activated Kir via a pertussis toxin-sensitive G protein. ICa in A-2 cells was sensitive to dihydropyridines and omega CTX MVIIC, less so to omega CgTX GVIA and insensitive to omega Aga IVa. In CB-1 expressing cells, cannabinoid agonist inhibited only the omega CTX MVIIC-sensitive component of ICa. Inhibition of Q-type ICa was voltage dependent and PTX sensitive, thus similar in character to the well-studied modulation of N-type ICa. An endogenous cannabinoid, anandamide, activated Kir and inhibited ICa as efficaciously as potent cannabinoid agonist. Immunocytochemical studies with antibodies specific for class A, B, C, D, and E voltage-dependent calcium channel alpha 1 subunits revealed that AtT-20 cells express each of these major classes of alpha 1 subunit.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7472417      PMCID: PMC6578016     

Source DB:  PubMed          Journal:  J Neurosci        ISSN: 0270-6474            Impact factor:   6.167


  143 in total

1.  Ultrastructural localization of the CB1 cannabinoid receptor in mu-opioid receptor patches of the rat Caudate putamen nucleus.

Authors:  J J Rodriguez; K Mackie; V M Pickel
Journal:  J Neurosci       Date:  2001-02-01       Impact factor: 6.167

2.  Localization and mechanisms of action of cannabinoid receptors at the glutamatergic synapses of the mouse nucleus accumbens.

Authors:  D Robbe; G Alonso; F Duchamp; J Bockaert; O J Manzoni
Journal:  J Neurosci       Date:  2001-01-01       Impact factor: 6.167

3.  Cannabinoid receptor activation inhibits GABAergic neurotransmission in rostral ventromedial medulla neurons in vitro.

Authors:  C W Vaughan; I S McGregor; M J Christie
Journal:  Br J Pharmacol       Date:  1999-06       Impact factor: 8.739

4.  Activation of human D3 dopamine receptor inhibits P/Q-type calcium channels and secretory activity in AtT-20 cells.

Authors:  E V Kuzhikandathil; G S Oxford
Journal:  J Neurosci       Date:  1999-03-01       Impact factor: 6.167

5.  Structural domains of the CB1 cannabinoid receptor that contribute to constitutive activity and G-protein sequestration.

Authors:  J Nie; D L Lewis
Journal:  J Neurosci       Date:  2001-11-15       Impact factor: 6.167

6.  Presynaptically located CB1 cannabinoid receptors regulate GABA release from axon terminals of specific hippocampal interneurons.

Authors:  I Katona; B Sperlágh; A Sík; A Käfalvi; E S Vizi; K Mackie; T F Freund
Journal:  J Neurosci       Date:  1999-06-01       Impact factor: 6.167

7.  Endocannabinoids prevent β-amyloid-mediated lysosomal destabilization in cultured neurons.

Authors:  Janis Noonan; Riffat Tanveer; Allan Klompas; Aoife Gowran; Joanne McKiernan; Veronica A Campbell
Journal:  J Biol Chem       Date:  2010-10-05       Impact factor: 5.157

8.  The endocannabinoid 2-arachidonoylglycerol is responsible for the slow self-inhibition in neocortical interneurons.

Authors:  Silvia Marinelli; Simone Pacioni; Tiziana Bisogno; Vincenzo Di Marzo; David A Prince; John R Huguenard; Alberto Bacci
Journal:  J Neurosci       Date:  2008-12-10       Impact factor: 6.167

9.  Activation of cannabinoid CB1 and CB2 receptors suppresses neuropathic nociception evoked by the chemotherapeutic agent vincristine in rats.

Authors:  E J Rahn; A Makriyannis; A G Hohmann
Journal:  Br J Pharmacol       Date:  2007-06-18       Impact factor: 8.739

Review 10.  Activation of G-proteins in brain by endogenous and exogenous cannabinoids.

Authors:  Steven R Childers
Journal:  AAPS J       Date:  2006-03-10       Impact factor: 4.009

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.